Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy

Journal of Nephrology

Volumn 23, Issue 4, 2010, Pages 415-424

  Blouza, Samira ^a   Dakhli, Sabeur ^a   Abid, Hafaoua ^b   Aissaoui, Mohamed ^c   Ardhaoui, Ilhem ^c   Abdallah, Nejib Ben ^b   Brahim, Samir Ben ^c   Ghorbel, Imed Ben ^d   Salem, Nabila Ben ^c   Beji, Soumaya ^b   Chamakhi, Said ^c   Derbel, Adnene ^c   Derouiche, Fethi ^c   Djait, Faycal ^c   Doghri, Taieb ^c   Fourti, Yamina ^c   Gharbi, Faycel ^c   Jellouli, Kamel ^c   Jellazi, Nabil ^c   Kamoun, Kamel ^c   Khedher, Adel ^b   Letaief, Amel ^e   Limam, Ridha ^c   Mekaouer, Awatef ^c   Miledi, Riadh ^c   Nagati, Khemaies ^c   Naouar, Meriem ^c   Sellem, Sami ^c   Tarzi, Hichem ^c   Turki, Selma ^c   Zidi, Borni ^f   Achour, Abdellatif ^g   more..

^a Institut National de Nutrition Tunis   (Tunisia)

^b CHARLES NICOLLE HOSPITAL   (Tunisia)

^c Service de Médecine Interne Hôpital la Rabta ^*

^d LA RABTA HOSPITAL   (Tunisia)

^e FARHAT HACHED HOSPITAL   (Tunisia)

^f MILITARY HOSPITAL OF TUNIS   (Tunisia)

^g SAHLOUL UNIVERSITY HOSPITAL   (Tunisia)

Author keywords

Albuminuria; Diabetes mellitus, glycosaminoglycans; Nephropathy; Sulodexide

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; SULODEXIDE; GLYCOSAMINOGLYCAN;

ADULT; ALBUMIN EXCRETION RATE; ARTICLE; CLINICAL TRIAL; COUGHING; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIARRHEA; DIET RESTRICTION; DISEASE DURATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; EPIGASTRIC PAIN; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PROSPECTIVE STUDY; PROTEINURIA; RENAL SYSTEM PARAMETERS; TREATMENT DURATION; VOMITING; AGED; ALBUMINURIA; BLOOD; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; URINE;

ADMINISTRATION, ORAL; ADULT; AGED; ALBUMINURIA; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; FEMALE; GLYCOSAMINOGLYCANS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 77955440687     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
2. International Diabetes Federation. Diabetes atlas. 3rd ed. Brussels, Belgium; 2007.
3. Chaar A, Ben Nejah B, Alberti H, Achour N. Life quality of Type 2 diabetic patients in Tunis. 18th International Diabetes Federation congress, Paris, France, 23-28 August 2003. Poster 2810.
4. Alberti H, Boudriga N, Nabli M. Primary care in Tunisia: improving diabetes management. Diabetes Voice. 2003;48:21-23.
5. Brady HR, O'Meara YM, Brenner BM. Glomerular diseases. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicine. 16th ed. New York: McGraw-Hill; 2008:1674-1694.
6. International Diabetes Federation. Diabetes. Report 27/03/06. Available at: http://www.idf.org/webdata/docs/background-cairo.pdf. Accessed May 20, 2009.
7. Marshall SM. Recent advances in diabetic nephropathy. Postgrad Med J. 2004;80:624-633.
8. American Diabetes Association. Nephropathy in diabetes. Diabetes Care. 2004;27(Suppl 1):S79-S83.
9. Gross JL, De Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28:164-176.
10. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
11. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
12. Wolf G. Molecular mechanisms of angiotensin II in the kidney: emerging role in the progression of renal disease: beyond haemodynamics. Nephrol Dial Transplant. 1998;13:1131-1142. (Pubitemid 28227185)
13. Abaterusso C, Gambaro G. The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy. Treat Endocrinol. 2006;5:211-222.
14. Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med. 2001;345:910-912.
15. Solini A, Carraro A, Barzon I, Crepaldi G. Therapy with glycosaminoglycans lower albumin excretion rate in non-insulin dependent diabetic patients with microalbuminuria. Diabetes Nutr Metab. 1994;7:304-307.
16. Dedov I, Shestakova M, Vorontzov A, Palazzini E. A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant. 1997;12:2295-2300.
17. Poplawska A, Szelachowska M, Topolska J, Wysocka-Solowie B, Kinalska I. Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria. Diabetes Res Clin Pract. 1997;38:109-114.
18. Solini A, Vergnani L, Ricci F, Crepaldi G. Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care. 1997;20:819-823. (Pubitemid 27202534)
19. Sorrenti G, Glimaldi M, Canova N, Palazzini E, Melchionda N. Glycosaminoglycans as a possible tool for micro-and macro-albuminuria in diabetic patients: a pilot study. J Int Med Res. 1997;25:81-86.
20. Szelachowska M, Poplawska A, Topolska J, Kinalska I, Grimaldi M. A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients. Curr Med Res Opin. 1997;13:539-545.
21. Velussi M, Monte AD, Cernigoi AM, Dapas F. Glycosaminoglycans oral therapy reduces microalbuminuria, blood fibrinogen levels and limb arteriopathy clinical signs in patients with non-insulin dependent diabetes mellitus. Diabetes Nutr Metab. 1996;9:53-58.
22. Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol. 2002;13:1615-1625.
23. Heerspink HL, Greene T, Lewis JB, et al; Collaborative Study Group. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant. 2008;6:1946-1954.
24. Keryx Biopharmaceuticals. Press release, November 14, 2005. Available at: http://www.shareholder.com/keryx/releases. cfm. Accessed June 15, 2006.
25. Achour A, Kacem M, Dibej K, Skhiri H, Bouraoui S, El May M. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol. 2005;18:568-574. (Pubitemid 41824477)
26. Everitt BS. The analysis of repeated measures: a practical review with examples. Statistician. 1995;44:113-135.
27. SAS Institute. SAS/STAT software: changes and enhancements through release 6.11. Cary, NC: SAS Institute; 1996.
28. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110:921-927.
29. Yuyun MF, Dinneen SF, Edwards OM, Wood E, Wareham NJ. Absolute level and rate of change of albuminuria over 1 year independently predict mortality and cardiovascular events in patients with diabetic nephropathy. Diabet Med. 2003;20:277-282. (Pubitemid 36606119)
30. Powers AC. Diabetes mellitus. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, eds. Harrison's principle of internal medicine. 16th ed. New York: McGraw- Hill; 2008:2152-2180.
31. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia. 1989;32:219-226.
32. Gambaro G, van der Woude FJ. Glycosaminoglycans: use in treatment of diabetic nephropathy. J Am Soc Nephrol. 2000;11:359-368.
33. Yokoyama H, Hoyer PE, Hansen PM, et al. Immunohistochemical quantification of heparan sulfate proteoglycan and collagen IV in skeletal muscle capillary basement membranes of patients with diabetic nephropathy. Diabetes. 1997;46:1875-1880.
34. Cruickshanks KJ, Ritter LL, Klein R, Moss SE. The association of microalbuminuria with diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology. 1993;100:862-867.
35. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-2169.
36. Coccheri S, Scondotto G, Agnelli G, Palazzini E, Zamboni V; for the Arterial Arm of the SUAVIS (Sulodexide Arterial Venous Italian Study) group. Sulodexide in the treatment of intermittent claudication: results of a randomized, doubleblind, multicentre, placebo-controlled study. Eur Heart J. 2002;23:1057-1065.
37. Gambaro G, Cavazzana AO, Luzi P, et al. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int. 1992;42:285-291.
38. Parnetti L, Mari D, Abate G, et al. Vascular Dementia Italian Sulodexide Study (VA.D.I.S.S.): clinical and biological results. Thromb Res. 1997;87:225-233.
39. Gambaro G, Venturini AP, Noonan DM, et al. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int. 1994;46:797-806.
40. Condorelli M, Chiariello M, Dagianti A, et al. IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol. 1994;23:27-34.
41. Harenberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998;1:1-20. (Pubitemid 28037477)
42. Rubbi F, Caramazza R, Boccia S, et al. The effects of sulodexide on diabetic retinopathy. Minerva Cardioangiol. 2000;48(Suppl 1):81-82.
43. Leung WY, So WY, Tong PC, et al. The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy. Nephrol Dial Transplant. 2004;19:2519-2525.
44. Camamori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes. 2000;49:1399-1408.
45. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348:2285-2293.
46. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.